Creative Medical Technology announced positive two-year follow-up data in the StemSpine® pilot study, showing significant efficacy of the procedure in the treatment of chronic lower back pain.
StemSpine is a patented procedure that utilizes a patient’s own bone marrow aspirate for the treatment of chronic lower back pain. The system launched in the U.S. in 2019.
There were no safety-related concerns at up to two years, and the StemSpine procedure resulted in an efficacy rate of 87% in treated patients.
“The positive two-year data from our StemSpine pilot study are very encouraging, and we are excited to engage with practitioners on commercialization,” said Timothy Warbington, President and CEO. “To our knowledge, this pilot is the first demonstration of the clinical efficacy of injecting bone marrow aspirate in areas surrounding the disc, thereby repairing, remodeling and improving the blood supply around the disc and lower back area. We believe StemSpine represents an attractive non-surgical option for many of the millions of Americans who suffer from non-surgical chronic lower back pain.”
Creative Medical Technology announced positive two-year follow-up data in the StemSpine® pilot study, showing significant efficacy of the procedure in the treatment of chronic lower back pain.
StemSpine is a patented procedure that utilizes a patient's own bone marrow aspirate for the treatment of chronic lower back pain. The system launched...
Creative Medical Technology announced positive two-year follow-up data in the StemSpine® pilot study, showing significant efficacy of the procedure in the treatment of chronic lower back pain.
StemSpine is a patented procedure that utilizes a patient’s own bone marrow aspirate for the treatment of chronic lower back pain. The system launched in the U.S. in 2019.
There were no safety-related concerns at up to two years, and the StemSpine procedure resulted in an efficacy rate of 87% in treated patients.
“The positive two-year data from our StemSpine pilot study are very encouraging, and we are excited to engage with practitioners on commercialization,” said Timothy Warbington, President and CEO. “To our knowledge, this pilot is the first demonstration of the clinical efficacy of injecting bone marrow aspirate in areas surrounding the disc, thereby repairing, remodeling and improving the blood supply around the disc and lower back area. We believe StemSpine represents an attractive non-surgical option for many of the millions of Americans who suffer from non-surgical chronic lower back pain.”
Copy to clipboard 
